December 2024's Promising US Penny Stocks

As December 2024 unfolds, the U.S. stock market presents a mixed landscape, with the Dow Jones Industrial Average marking its fifth consecutive day of gains while the S&P 500 and Nasdaq Composite see minor declines. In this context, investors often turn to penny stocks—smaller or newer companies that can offer significant opportunities despite their somewhat outdated name. By focusing on those with strong financial foundations and potential for growth, investors can uncover hidden value in these lesser-known equities.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
Inter & Co (NasdaqGS:INTR)	$4.30	$1.85B	★★★★☆☆
QuantaSing Group (NasdaqGM:QSG)	$3.08	$103.25M	★★★★★★
BAB (OTCPK:BABB)	$0.84	$6.43M	★★★★★★
Pangaea Logistics Solutions (NasdaqCM:PANL)	$4.90	$234.98M	★★★★★☆
ZTEST Electronics (OTCPK:ZTST.F)	$0.25	$8.83M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.85	$86.14M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$2.59	$49.54M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.62	$22.53M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9125	$76.47M	★★★★★☆

Click here to see the full list of 732 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Blade Air Mobility (NasdaqCM:BLDE)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Blade Air Mobility, Inc. offers air transportation alternatives to alleviate congested ground routes in the United States and has a market cap of approximately $325.79 million.

Operations: The company's revenue is derived from two main segments: Medical, which generated $142.42 million, and Passenger services, contributing $99.39 million.

Market Cap: $325.79M

Blade Air Mobility, Inc. has been actively pursuing strategic growth through acquisitions, with $140 million earmarked for tactical investments in its medical segment. Despite a market cap of approximately $325.79 million and revenue from medical ($142.42 million) and passenger services ($99.39 million), the company remains unprofitable, with a net loss of $17.51 million for the first nine months of 2024. The management team is experienced, and the company is debt-free with sufficient cash runway for over three years based on current free cash flow levels, though shareholder dilution has occurred recently by 4.9%.

• Jump into the full analysis health report here for a deeper understanding of Blade Air Mobility.
• Examine Blade Air Mobility's earnings growth report to understand how analysts expect it to perform.

Gevo (NasdaqCM:GEVO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Gevo, Inc. is a carbon abatement company with a market cap of $349.09 million.

Operations: The company generates revenue from two main segments: Gevo, which contributes $0.96 million, and Renewable Natural Gas, accounting for $14.63 million.

Market Cap: $349.09M

Gevo, Inc., with a market cap of US$349.09 million, operates in the renewable energy sector and is currently unprofitable. The company reported third-quarter sales of US$1.97 million, down from US$4.53 million the previous year, with a net loss widening to US$21.16 million. Gevo's financial health shows more cash than total debt and short-term assets exceeding liabilities, providing some stability despite ongoing losses. Recent developments include an extended partnership with LG Chem to commercialize its Ethanol-to-Olefins technology for sustainable products, signaling potential future revenue streams if successfully executed and scaled up in the bioplastic market.

• Click here to discover the nuances of Gevo with our detailed analytical financial health report.
• Learn about Gevo's future growth trajectory here.

Clover Health Investments (NasdaqGS:CLOV)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Clover Health Investments, Corp. offers Medicare Advantage plans in the United States and has a market cap of approximately $1.60 billion.

Operations: The company's revenue is derived entirely from the United States, totaling $2.12 billion.

Market Cap: $1.6B

Clover Health Investments, Corp., with a market cap of US$1.60 billion, remains unprofitable but has shown progress by significantly narrowing its net loss from US$41.47 million to US$9.16 million in the latest quarter compared to the previous year. The company is debt-free and maintains a stable cash runway exceeding three years based on current free cash flow levels. Despite shareholder dilution over the past year, Clover's short-term assets comfortably cover both short- and long-term liabilities. Recent initiatives include launching enhanced Medicare Advantage plans in New Jersey for 2025, aiming to offer competitive healthcare options amid rising costs for seniors.

• Take a closer look at Clover Health Investments' potential here in our financial health report.
• Review our growth performance report to gain insights into Clover Health Investments' future.

Turning Ideas Into Actions

• Gain an insight into the universe of 732 US Penny Stocks by clicking here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com